Navigation Links
AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis

AM Pharma Continues Its Success with Positive Phase IIa Clinical Trial Results

First clinical Results Confirm Potential New Application of Key Product in AM-Pharma's Pipeline

BUNNIK, The Netherlands, July 9, 2007-AM-Pharma B.V., the biopharmaceutical company developing novel therapeutics to treat infectious and inflammatory diseases, today announced the positive clinical results of its Phase IIa Alkaline Phosphatase (AP) trial for patients with ulcerative colitis, a chronic and relapsing inflammatory bowel disease affecting the colon.

In this recent trial, AP was used in the treatment of 21 hospitalised patients suffering from moderate to severe ulcerative colitis, who had failed to show improvement using existing treatments of steroids and immunosuppressants. The AP therapy was administered through a duodenal drip at a dose of 10mg AP per day.

In the trial, patients showed clinically relevant improvement after the seven day treatment period, in the two main clinical parameters (Truelove-Witts and Mayo scores) measured three weeks after starting the AP trial.

Patient response rates after three weeks were 63% on the Truelove-Witts score and 47% on the Mayo score. Complete remission after three weeks was reached by 21% of patients on the Truelove-Witts score and by 5% of patients on the Mayo score. After 63 days, 79% of patients showed a response and 26% of patients were in complete remission according to the Truelove-Witts score. No serious adverse effects or treatment-related withdrawals were reported.

AP is a unique therapy for ulcerative colitis based on the dephosphorylation and detoxification of a group of bacterial endotoxins called lipopolysaccharides, which can cause inflammation in the colon. AM-Pharma's patented AP treatment has already shown positive results in trials for treatment of acute renal failure and sepsis.

Bart Wuurman, CEO commented: "It's fantastic
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AM-Pharma Announces Positive Results of a Phase IIa Clinical Trial with Alkaline Phosphatase in Acute Renal Failure
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:2/27/2015)... -- Pomerantz LLP is investigating claims on behalf of investors ... VTAE ).  Such investors are advised to ... or 888-476-6529, ext. 237. The investigation ... directors have violated Sections 10(b) and 20(a) of the ... February 27, 2015, the Company announced that its partner ...
(Date:2/27/2015)... Securities lawyers at Dunnam & Dunnam ... (NASDAQ: SLXP ) in connection with a ... are encouraged to contact attorney Hamilton Lindley by ... upon the shareholder value of the transaction. Under terms ... $158.00 per share in cash. At least one analyst ...
(Date:2/27/2015)... 2015 Report Details   ... trends, R&D progress, and predicted revenues ,Where is the ... the commercial prospects for this market and related technologies? ... other trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
...  Hanger Orthopedic Group, Inc. (NYSE: HGR ) announced ... for the quarter ended December 31, 2011, on Thursday, February ... press release announcing the results for the quarter ended December ... February 8, 2012 after the close of the market. A ...
... DIEGO, Jan. 9, 2012 Amylin Pharmaceuticals, Inc. (Nasdaq: ... 2012, with a strong focus on driving the global commercial ... at the 30th Annual J.P. Morgan Healthcare Conference in San ... highlighted steps the company is taking to prepare for the ...
Cached Medicine Technology:Hanger Orthopedic Group, Inc. Announces Fourth Quarter 2011 Earnings Release Conference Call 2Amylin Outlines Corporate Strategy to Maximize Global Value of Diabetes Franchise and Advance Key Pipeline Candidates 2Amylin Outlines Corporate Strategy to Maximize Global Value of Diabetes Franchise and Advance Key Pipeline Candidates 3Amylin Outlines Corporate Strategy to Maximize Global Value of Diabetes Franchise and Advance Key Pipeline Candidates 4
(Date:3/1/2015)... 01, 2015 A federal court ... ) scheduled to go to trial in October ... witness to provide testimony regarding the role an ... the Profemur device, Bernstein Liebhard LLP comments. According ... Northern District of Iowa on February 25th, Wright ...
(Date:3/1/2015)... 01, 2015 “ The Barrel Mill ” ... Report, which takes a look at the latest and coolest ... host of NewsWatch and a technology expert, conducted the review ... flavor to drinks. , According to Home Distillation of Alcohol, ... spirits. Well, there’s a pretty cool product that’ll help anyone ...
(Date:2/28/2015)... Heart diseases are on the rise ... urban adult population and 5 percent of rural adult ... 20-30 percent of them require specialized investigation and treatment ... vascular diseases (CVD). , A division of Indian Business ... report titled “Indian Coronary Stent Market Forecast to 2019”. ...
(Date:2/28/2015)... February 28, 2015 The Classic ... offering a new special. Throughout all of March ... , This service can help overall ... and pain. Patients may notice certain symptoms that suggest ... These symptoms include: , 1.    Pain, clicking, and popping ...
(Date:2/28/2015)... A study out of the University of ... for the treatment of a hereditary ocular condition that ... by Dr. Robert MacLaren, professor of ophthalmology at the ... Journal on January 16, 2014 , the study treated ... that mostly affects men and leads to the degeneration ...
Breaking Medicine News(10 mins):Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2
... only a few basic ways to fight viruses. A vaccine can ... invade the body//. If a virus manages to establish itself, a ... its spread. And if all else fails, a doctor may quarantine ... scientists are exploring a fundamentally different strategy to fight viruses. They ...
... Trusts have welcomed a move to bring an end to the ... ,Till now, when a health trust falls into deficit, ... debts but in addition, some money is cut off from its ... this has meant that some health trusts find it virtually impossible ...
... provide detailed information on how well a transplanted heart ... as the Allomap test, is currently used to detect ... invasive heart muscle biopsies, but has now been shown ... the heart before pumping, and the electrical properties of ...
... the popular anti-clotting drug clopidogrel (Plavix) when taken along with ... adverse bleeding event.// ,The study, to be ... Session on March 27 at 9 am (abstract 1027-18), found ... worsen bleeding after off-pump heart bypass surgery. ...
... children, yet the number of pediatric orthopedists trained to ... decreasing nationwide. The management of fractures in children is ... is needed to provide the best care for these ... for Special Surgery (HSS). ,Fractures in ...
... of Indian MPs has come together to launch a fight ... start a massive awareness drive and also seeking a special ... that at least two people die of the infectious disease ... have decided to form a group next month and to ...
Cached Medicine News:Health News:Scientists Explore Ways to Lure Viruses to Their Death 2Health News:Scientists Explore Ways to Lure Viruses to Their Death 3Health News:Double-penalty System for Bankrupt Health Trusts Lifted 2Health News:Gene Test Shown to Measure Heart Function After Transplant 2Health News:Plavix Safe During and After Heart Bypass 2Health News:Number of Specialists Best at Treating Children's Fractures Decreasing 2Health News:Number of Specialists Best at Treating Children's Fractures Decreasing 3Health News:Indian Parliamentarians Join to Fight Against TB 2
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: